Semaglutide

Semaglutide is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 5 labelled variants: 5mg, 10mg, 15mg, 20mg, and 30mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, Semaglutide sits alongside Cagrilintide + Semaglutide, Retatrutide, and Tesamorelin. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, Semaglutide is generally treated as a 34-amino acid GLP-1 receptor agonist analog with a C18 fatty diacid modification enabling reversible albumin binding. Semaglutide binds the GLP-1 receptor (GLP-1R), a class B GPCR, with high affinity and activates Gs-coupled adenylyl cyclase to elevate intracellular cAMP. Downstream signalling proceeds via PKA-mediated phosphorylation of CREB and other substrates, with additional engagement of EPAC pathways depending on cell type. The C18 fatty diacid chain, linked at Lys26 via a short spacer, confers albumin binding (Kd ~3 µM) that extends circulating half-life to approximately one week in pharmacokinetic models — making it a standard comparator in peptide persistence and receptor-occupancy kinetic studies. Its primary sequence shares 94% homology with native GLP-1(7-36)amide.

Research interest centres on how fatty acid conjugation modulates receptor binding kinetics, internalisation rates, and cAMP desensitisation relative to shorter-acting GLP-1 analogs. The high GLP-1R selectivity (versus GcgR or GIPR) makes it a clean single-pathway reference standard in multi-receptor comparator assays. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Semaglutide behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare Semaglutide with Cagrilintide + Semaglutide, Retatrutide, and Tesamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.